CTOs on the Move

Copernicus

www.cgsys.com

 
Copernicus is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.cgsys.com
  • 11000 Cedar Ave Ste 145
    Cleveland, OH USA 44106
  • Phone: 216.231.0227

Executives

Name Title Contact Details

Similar Companies

Madeira Therapeutics

Madeira Therapeutics is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Senti Bio

Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address.

Unigene Laboratories

Unigene Laboratories, Inc. (Unigene) is a biopharmaceutical company engaged in the research, production and delivery of small proteins, referred to as peptides, for medical use. The Company has a manufacturing technology for producing many peptides

CepTor Corporation

CepTor Corporation is a Cockeysville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scifluor Life Sciences

SciFluor Life Sciences is a drug discovery company applying expertise in fluorine chemistry to create a portfolio of differentiated best-in-class therapeutics. The company is creating a portfolio of new chemical entities (NCEs) directed towards precedented biological targets. SciFluor strategically incorporates fluorine or fluorine-containing groups to design drugs with improved pharmacological profiles that provide important benefits over existing therapies such as improved safety, efficacy, more convenient dosing and better patient compliance. This capital-efficient and de-risked drug discovery approach has resulted in the generation of a proprietary pipeline of novel and differentiated small molecule drugs across a range of therapeutic categories and disease areas including retinal disease, CNS disorders, fungal and bacterial infections and inflammatory disease.